Abattis Bioceuticals Corp (CNSX:ATT) Director William Panenka sold 90,000 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of C$0.53, for a total value of C$47,700.00.
William Panenka also recently made the following trade(s):
- On Tuesday, January 16th, William Panenka sold 25,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.67, for a total value of C$16,750.00.
- On Tuesday, December 12th, William Panenka sold 100,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.48, for a total value of C$48,000.00.
Shares of Abattis Bioceuticals Corp (CNSX:ATT) traded up C$0.01 during trading hours on Friday, hitting C$0.61. The stock had a trading volume of 1,710,000 shares, compared to its average volume of 2,970,000. Abattis Bioceuticals Corp has a 1 year low of C$0.05 and a 1 year high of C$0.74. The stock has a market capitalization of $136.43 and a PE ratio of -15.25.
COPYRIGHT VIOLATION WARNING: “Abattis Bioceuticals Corp (ATT) Director Sells C$47,700.00 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/19/abattis-bioceuticals-corp-att-director-sells-c47700-00-in-stock.html.
Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets.
Receive News & Ratings for Abattis Bioceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abattis Bioceuticals and related companies with MarketBeat.com's FREE daily email newsletter.